Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04191834 bronchodilatory effects in asthma
NCT00723021Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-04191834 in asthma (5 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Forced Expiratory Volume in 1 Second. Started Jul 2008; status: completed.
02
Drugs
PF-04191834
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00723021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723021.